Pelthos Therapeutics Company Profile - aVenture Research
Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on cutaneous infectious diseases, with ZELSUVMI gel treating molluscum contagiosum.
Public company
Pelthos Therapeutics Inc. emerged through a series of corporate name changes from Chromocell Therapeutics Corporation, originally a non-opioid pain treatment developer, that became Channel Therapeutics Corporation and then amended its articles of incorporation to adopt the name Pelthos Therapeutics Inc. The company's asset portfolio includes XEPI (ozenoxacin) Cream, 1%, a topical impetigo treatment, and XEGLYZE (abametapir), a topical head lice treatment.
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on cutaneous infectious disease products. Its ZELSUVMI gel is a topical nitric oxide-releasing therapy for molluscum and the first and only prescription therapy approved for patients, parents, and caregivers to use at home.